ArticleEndocrine2002
Estradiol and progesterone regulate oxytocin receptor binding and expression in human breast cancer cell lines.
Article in Endocrine, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 25 citations in OpenAlex.
- Extracting Knowledge from Machine Learning Models to Diagnose Breast Cancer.Life (Basel, Switzerland) · 2025Article
- Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.Journal of medicinal chemistry · 2024Review
- The role of the oxytocin system in the resilience of patients with breast cancer.Frontiers in oncology · 2023Review
- High Oxytocin Receptor Expression Linked to Increased Cell Migration and Reduced Survival in Patients with Triple-Negative Breast Cancer.Biomedicines · 2022Article
- Sex Differences and Estrous Influences on Oxytocin Control of Food Intake.Neuroscience · 2020Article
- Review
- Oxytocin in metabolic homeostasis: implications for obesity and diabetes management.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2019Review
- Autism, oxytocin and interoception.Neuroscience and biobehavioral reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of estradiol (E2) and progesterone on the oxytocin receptor (OTR) were investigated in MCF-7 and Hs 578T human breast cancer cell lines. OTR messenger RNA and protein were identified by reverse transcriptase polymerase chain reaction (PCR) and solution-phase hybridization-RNase protection assay, and Western blot analysis, respectively, in cell lines and in cancerous breast tissue removed from women at mastectomy. Cells were exposed to E2, progesterone, or vehicle (each steroid, 10(-10)-10(-6) M) for 24 h and harvested for extraction of RNA. The OTR PCR product was increased by E2 (10(-7) M, p < 0.05, or 10(-6) M, p < 0.01 vs control) and decreased by progesterone (control vs 10(-7) or 10(-6) M, each p < 0.005). Hs578T cells were cultured in the presence or absence of E2 (10(-6) M) or progesterone (10(-6) M) for 24 h and binding was measured. For the E2-exposed cells, the Kd (p < 0.05), and Bmax (p < 0.01) were higher whereas for the progesterone-treated cells the Kd (p < 0.05) and Bax were lower than control cells. E2 and progesterone not only regulate OTR expression and binding in normal mammary myoepithelium but also in malignant mammary cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.